PKCalpha抗体—艾普蒂

+ +

•  

   

     All lanes use the Antibody at 1:2K dilution for 1 hour at room temperature.    

  
  

•  

   

     All lanes use the Antibody at 1:1K dilution for 1 hour at room temperature.    

  
  

•  

   

     Western blot analysis of PKC alpha expression in HEK293 cell lysate.    

  
  

•  

   

     Immunofluorescent analysis of Hela cells, using PKC alpha Antibody .    

  
  

•  

   

     Immunofluorescent analysis using the Antibody at 1:50 dilution.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded Human pituitary tumor, using the Antibody at 1:100 dilution.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded Human thymoma, using the Antibody at 1:200 dilution.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded Human melanoma, using the Antibody at 100 dilution.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human colon, using PKC alpha Antibody.    

  
  

The protein kinase C alpha (PKCα) antibody is a crucial tool for studying the PKCα enzyme, a member of the serine/threonine kinase family involved in diverse cellular signaling pathways. PKCα, part of the classical PKC subfamily (cPKC), is activated by calcium ions, diacylglycerol (DAG), and phospholipids. It regulates processes like cell proliferation, apoptosis, differentiation, and migration by phosphorylating downstream targets. Dysregulation of PKCα has been implicated in cancer, cardiovascular diseases, and metabolic disorders, making it a focus of therapeutic research.

PKCα antibodies are designed to detect endogenous PKCα protein in various experimental applications, including Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry. These antibodies typically target specific epitopes within the regulatory or catalytic domains of PKCα, enabling researchers to study its expression, localization, and post-translational modifications (e.g., phosphorylation) under different physiological or pathological conditions. Monoclonal and polyclonal variants are available, with specificity validated using knockout controls or siRNA-mediated silencing.

Research using PKCα antibodies has revealed its role in tumor progression, where it often exhibits context-dependent oncogenic or tumor-suppressive activity. In neuroscience, PKCα is linked to synaptic plasticity and neurodegenerative diseases. The antibody’s utility extends to drug discovery, particularly in evaluating PKC inhibitors for cancer therapy. Proper validation, including checks for cross-reactivity with other PKC isoforms (e.g., PKCβ, PKCγ), is critical for experimental accuracy.